Biopharmaceutical company developing T-cell therapies for solid tumor cancers.
About
Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering novel T-cell therapies for cancer. They utilize a proprietary T-cell receptor (TCR) platform to engineer T-cells that can identify and target cancer cells, aiming to significantly impact cancer treatment outcomes. Their pipeline includes therapies for various solid tumor types.
Tags
Total Employees
191
Current headcount
Performance
Company Timeline
No timeline data for this period
Score Breakdown
50Traction
60Team
30Visibility
28Profile
50Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Adaptimmune Therapeutics do?
Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering novel T-cell therapies for cancer. They utilize a proprietary T-cell receptor (TCR) platform to engineer T-cells that can identify and target cancer cells, aiming to significantly impact cancer treatment outcomes. Their pipeline includes therapies for various solid tumor types.
How much funding has Adaptimmune Therapeutics raised?
Adaptimmune Therapeutics has raised a total of $107M in funding. The most recent round on record is Series A.
Where is Adaptimmune Therapeutics headquartered?
Adaptimmune Therapeutics is headquartered in Abingdon, United Kingdom.
When was Adaptimmune Therapeutics founded?
Adaptimmune Therapeutics was founded in 2008.
What industry does Adaptimmune Therapeutics operate in?
Adaptimmune Therapeutics operates in Biotechnology, Pharmaceuticals, Drug Discovery, Cancer Immunotherapy, Cell Therapy, Oncology.
How many employees does Adaptimmune Therapeutics have?
Adaptimmune Therapeutics has approximately 191 people on record.
Similar Startups